SWOG clinical trial number
CTSU/A051701

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas -

Closed
Phase
Abbreviated Title
Phase II/III study of venetoclax (ABT-199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double expressing lymphomas
Status Notes
Effective December 14, 2023, A051701 is permanently closed to new patient registration.

Closed
12/14/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Venetoclax

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org ).

Publication Information Expand/Collapse

2024

Randomized Phase II/III Study of R-CHOP +/- Venetoclax in Previously Untreated MYC/BCL2 Double Expressor Diffuse Large B Cell Lymphoma (DLBCL): Alliance A051701

J Abramson;S Geyer;L Pederson;S Giri;E Hsi;R Little;S Gore;D Landsburg;H Cherng;B Kahl;JW Friedberg;N Bartlett;J Leonard ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 7012)

2021

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance 051701

J Abramson;A Ruppert;S Giri;A Hudson;E Hsi;R Little;S Gore;A Vallurupalli;D Landsburg;B Kahl;JW Friedberg;N Bartlett;J Leonard American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #523

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase